SAN FRANCISCO--(BUSINESS WIRE)--Today Obagi Medical Products, Inc. (Nasdaq: OMPI), the leader in topical aesthetic and therapeutic skin health systems, announced the successful completion of a 10-week study comparing CLENZIderm M.D.TM Acne Therapeutic Systems’ 3-step acne system for normal-to-oily skin to a leading combination prescription benzoyl peroxide (BPO)/clindamycin product at the American Academy of Dermatology’s Annual Meeting in San Francisco. The data, compiled from the 139-subject study, show that patients with mild-to-moderately severe acne experienced a comparable reduction in inflammatory and a greater reduction in non-inflammatory lesions when using the CLENZIderm M.D. System compared to the leading BPO/clindamycin product.
